SCHEMBL24826714

SCHEMBL24826714

CO[C@H]1CCN(C(=O)OC(C)(C)C)C[C@H]1OCCO[Si](C)(C)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ GPR119 Q8TDV5 4/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ PTPN2 P17706 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ PTPN6 P29350 1/20 0.36
▸ NR1H2 P55055 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ ALOX5AP P20292 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24826137 0.87 RECQL (0.43) RECQLHPGDGPR119ALDH1A1MEN1
SCHEMBL29206652 0.87 RECQL (0.43) RECQLHPGDGPR119ALDH1A1MEN1
SCHEMBL29206650 0.87 RECQL (0.43) RECQLHPGDGPR119ALDH1A1MEN1
SCHEMBL24826699 0.87 RECQL (0.43) RECQLHPGDGPR119ALDH1A1MEN1
SCHEMBL29124147 0.82 ALDH1A1 (0.38) RECQLHPGDGPR119ALDH1A1MEN1
SCHEMBL29124148 0.82 ALDH1A1 (0.38) RECQLHPGDGPR119ALDH1A1MEN1
SCHEMBL5109520 0.82 GPR119 (0.48) RECQLHPGDGPR119USP2SMN1; SMN2
SCHEMBL24197695 0.79 NR1H2 (0.43) RECQLHPGDGPR119ALDH1A1MEN1
SCHEMBL850416 0.79 GPR119 (0.46) RECQLHPGDGPR119USP2SMN1; SMN2
SCHEMBL29124139 0.77 MAPT (0.39) RECQLHPGDGPR119ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022271612-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 — — WO disclosed
WO-2022271612-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 — — WO disclosed
Send feedback